Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies targeting protein dysregulation, particularly in neurodegenerative diseases and rare peripheral amyloid diseases. The company leverages deep expertise in the biology of misfolded proteins to advance investigational antibody therapies and innovative platforms like CYTOPE. Its pipeline features key programs such as prasinezumab, a humanized monoclonal antibody in phase 3 trials for Parkinson's disease and synucleinopathies through collaboration with Roche; coramitug in phase 3 for transthyretin amyloidosis with cardiomyopathy via partnership with Novo Nordisk; and BMS-986446 in phase 2 for Alzheimer's disease with Bristol Myers Squibb. Additional wholly-owned candidates include PRX012 and PRX019 in early clinical stages for Alzheimer's and other neurodegenerative conditions, alongside preclinical efforts like the dual Aβ-tau vaccine PRX123. Prothena Corporation plc maintains strategic collaborations that support its mission to deliver transformative treatments for devastating diseases affecting millions worldwide. Incorporated in 2012 and headquartered in Dublin, Ireland, it operates at the forefront of neuroscience innovation in the healthcare sector.